💊 Big Pharma not doing enough for access to drugs says new report; Novartis looking to offload ophthalmology and respiratory units
#218 | Chicken burgers from the lab
Hello, and welcome back to The Kable.
Indian drug makers and regulatory bodies continue to face off against each other, with the US FDA hitting yet another Lupin plant with a Form 483 after a preapproval inspection. And, in possibly more damning news, nine drugs made in India's pharma manufacturing hub of Himachal Pradesh have failed safety tests.
Not content with hiving off Sandoz into a standalone unit, Novartis is reportedly considering selling its ophthalmology and respiratory units.
Two decades-old CDMOs, Kindeva and Meridian, are merging into one global drug-device CDMO. In the past two years, Kindeva and Meridian were acquired by healthcare investment firm Altaris.
Time magazine's annual list of best inventions of the year includes 14 medical devices this time around. The devices range from robotic surgery to accessibility to wearables and patient monitoring. Our favourite of these is Esper's bionic hand which looks totally rad. Do you have a favourite?
Keep reading with a 7-day free trial
Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.